74 completed, 28 unknown, 12 terminated, 9 recruiting. 44 Phase 4, 41 Phase 3, 26 Phase 2, 7 Not applicable, 7 Phase 1.
Follow evolocumab: new trials by email Literature Review of evolocumab trials Research Report on evolocumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling Intervention 1, Intervention 3, Intervention 2 - Atherosclerosis Cerebral, Carotid Plaque | Phase 4 | Not yet recruiting | Keqiang Zhao | 120 | 2027-01-01 | 2026-09-15 |
| Mechanistic Clinical Trial of PCSK9 Inhibition for AAA Evolocumab, Placebo - Abdominal Aortic Aneurysm | Early Phase 1 | Not yet recruiting | University of Pennsylvania | 44 | 2026-12-01 | 2026-04-20 |
| Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran) - Melanoma | Not applicable | Recruiting | University of Colorado, Denver | 40 | 2026-10-19 | 2026-11-02 |
| Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference) - Healthy Participants | Phase 1 | Completed | Amgen | 405 | 2026-04-21 | 2026-10-02 |
| YN001-004 in Patients With Coronary Atherosclerosis in Australia Dose 1 YN001, Dose 2 YN001, Evolocumab - Coronary Artery Disease, Coronary Atherosclerotic Disease | Phase 2 | Terminated | Beijing Inno Medicine Co., Ltd. | 3 | 2026-02-25 | 2026-09-23 |
| Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose Evolocumab Drug Substance A, Evolocumab Drug Substance B - Healthy Participants, Pharmacokinetics | Phase 1 | Completed | Amgen | 405 | 2026-01-16 | 2026-08-17 |
| Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis Evolocumab 140 MG/ML [Repatha], Conventional lipid-lowering therapy - Hypertriglyceridemia Induced Acute Pancreatitis | Not applicable | Recruiting | General Hospital of Shenyang Military Region | 60 | 2026-01-02 | 2026-09-25 |
| Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial Evolocumab(420 mg injections) - Acute Stroke | Phase 4 | Completed | The Affiliated Hospital of Xuzhou Medical University | 60 | 2025-12-20 | 2026-07-13 |
| CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS Evolocumab, Serial photon-counting coronary computed tomography angiography, Standard Lipid-Lowering Therapy - Coronary, Coronary Artery Disease | Phase 4 | Recruiting | West China Hospital | 232 | 2025-11-19 | 2026-10-07 |
| PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy PCSK9 inhibitor - Acute Ischemic Stroke | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 478 | 2025-09-15 | 2025-09-15 |
| Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study PCSK9 inhibitor, Standard Lipid-Lowering Therapy - Coronary Artery Disease | Phase 4 | Not yet recruiting | Hanyang University Seoul Hospital | 352 | 2025-07-01 | 2025-07-24 |
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia Atorvastatin, Simvastatin, Rozuvastatin - Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 2382 | 2025-04-15 | 2025-08-03 | |
| Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks - Dyslipidemias | Phase 2 | Recruiting | NewAmsterdam Pharma | 69 | 2024-12-02 | 2026-04-09 |
| A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Evolocumab, Nivolumab - Metastatic Renal Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2024-08-07 | 2026-10-15 |
| Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe, Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe - Dyslipidemias, Statin Adverse Reaction | Phase 4 | Unknown | University of Salerno | 130 | 2024-05-01 | 2024-04-24 |
| Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran - ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction | Not applicable | Not yet recruiting | Jena University Hospital | 300 | 2024-04-01 | 2024-03-07 |
| Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism Evolocumab - Acute Metabolic Effects of Evolocumab and Atorvastatin | Early Phase 1 | Unknown | Region Stockholm | 8 | 2024-02-01 | 2023-11-18 |
| Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke Statins, Evolocumab - Acute Ischemic Stroke | Unknown | Xuanwu Hospital, Beijing | 80 | 2023-12-01 | 2023-11-18 | |
| In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease Inclisiran sodium, Placebo, Ezetimibe - Atherosclerotic Cardiovascular Disease | Completed | Novartis Pharmaceuticals | 204691 | 2023-11-03 | 2024-05-08 |
Showing 20 of 138. Sign in to see all of them.
Hypercholesterolemia (43) · Hyperlipidemias (22) · Dyslipidemias (15) · Atherosclerosis (13) · Coronary Artery Disease (12) · Hyperlipoproteinemia Type II (11) · Acute Coronary Syndrome (10) · Cardiovascular Diseases (9) · Hypercholesterolemia, Autosomal Dominant, 3 (9) · ST Elevation Myocardial Infarction (8) · Ischemic Stroke (7) · Diabetes Mellitus, Type 2 (5) · Homozygous Familial Hypercholesterolemia (5) · Carotid Stenosis (3) · Coronary Disease (3)
Amgen (44) · Johns Hopkins University (3) · NYU Langone Health (3) · Novartis Pharmaceuticals (3) · Brigham and Women's Hospital (2) · Federico II University (2) · Inova Health Care Services (2) · LIB Therapeutics LLC (2) · Leonardo Clavijo (2) · Policlinico Casilino ASL RMB (2) · Annapoorna Kini (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliera Ordine Mauriziano di Torino (1) · Beijing Anzhen Hospital (1) · Beijing Inno Medicine Co., Ltd. (1)
United States (67) · Canada (32) · Australia (25) · Italy (23) · Belgium (21) · France (21) · Spain (21) · Netherlands (20) · United Kingdom (20) · China (18) · Czechia (18) · Germany (18) · South Africa (18) · Denmark (17) · Hungary (15)
Annapoorna Kini, MD (2) · Evan A Stein, MD PhD (2) · Leonardo Clavijo, MD, PhD (2) · Allison Hays, MD (1) · Andreas Birkenfeld, MD, PhD (1) · Andrei C Sposito, MD,Phd (1) · Andreja Rehberger Likozar, MD (1) · Anil K Chandraker, MD (1) · Anne Gangloff, MD PhD FRCPC (1) · Anne-Marie Carreau, MD FRCPC (1) · Bernd Hohenstein, MD, PhD (1) · Bo Hu, Doctor (1) · Caitlin Bell, MD (1)
PMID 33078867, PMID 25773607, PMID 28304224, PMID 24014831, PMID 35314069, PMID 40780143, PMID 11277825, PMID 16226162, PMID 21543628, PMID 221537, PMID 23884353, PMID 24161333, PMID 25282520, PMID 25825402, PMID 26039521, PMID 26578202, PMID 26999484, PMID 27039291, PMID 27066336, PMID 27264224, PMID 28477848, PMID 28844508, PMID 28859947, PMID 28927706, PMID 29066265, PMID 29133605, PMID 29530884, PMID 29626068, PMID 29653628, PMID 29898218, PMID 30403574, PMID 30540337, PMID 30586750, PMID 30779243, PMID 30851062, PMID 30897995, PMID 30953107, PMID 31116355, PMID 31196453, PMID 31248666, PMID 31479722, PMID 31504418, PMID 31748467, PMID 31800032, PMID 31887831, PMID 31917184, PMID 32268367, PMID 32312223, PMID 32318641, PMID 32347885
2015 (6), 2017 (5), 2014 (3), 2018 (3), 2016 (2), 2023 (1), R01HL166991 (1)